Olumuyiwa Elijah Ariyo

Olumuyiwa Elijah Ariyo

Auto-generated profile, based on publicly available information

Olumuyiwa Elijah Ariyo

Federal Teaching Hospital Abakaliki

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
Elijah Kolawole OladipoElijah Kolawole Oladipo
Elijah Kolawole Oladipo
AAAyodeji Folorunsho Ajayi
Ayodeji Folorunsho Ajayi
OAOlumuyiwa Elijah Ariyo
Olumuyiwa Elijah Ariyo
Olugbenga Samson OnileOlugbenga Samson Onile
Olugbenga Samson Onile
EJEsther Moradeyo Jimah
Esther Moradeyo Jimah
JOJulius Kola Oloke
Julius Kola Oloke
Stimulation and generation of T and B cell-mediated long-term immune response are essential for the curbing of a deadly virus such as SAR-CoV-2 (Severe Acute Respiratory Corona Virus 2). Immunoinformatics approach in vaccine design takes advantage of antigenic and non-allergenic epitopes present on the spike glycoprotein of SARS-CoV-2 to elicit immune responses. T cells and B cells epitopes were predicted, and the selected residues were subjected to allergenicity, antigenicity and toxicity screening which were linked by appropriate linkers to form a multi-epitope subunit vaccine. The physiochemical properties of the vaccine construct were analyzed, and the molecular weight, molecular formula, theoretical isoelectric point value, half-life, solubility score, instability index, aliphatic index and GRAVY were predicted. The vaccine structure was constructed, refined, validated, and disulfide engineered to get the best model. Molecular binding simulation and molecular dynamics simulation were carried out to predict the stability and binding affinity of the vaccine construct with TLRs. Codon acclimatization and in silico cloning were performed to confirm the vaccine expression and potency. Results obtained indicated that this novel vaccine candidate is non-toxic, capable of initiating the immunogenic response and will not induce an allergic reaction. The highest binding energy was observed in TLR4 (Toll-like Receptor 4) (−1398.1), and the least is TLR 2 (−1479.6). The steady rise in Th (T-helper) cell population with memory development was noticed, and IFN-g (Interferon gamma) was provoked after simulation. At this point, the vaccine candidate awaits animal trial to validate its efficacy and safety for use in the prevention of the novel COVID-19 (Coronavirus Disease 2019) infections.

1 January 2026 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
AAAkinwumi A. Akinbodewa
Akinwumi A. Akinbodewa
OAOlorunfemi A.
Olorunfemi A.
OAOlumuyiwa E. Ariyo
Olumuyiwa E. Ariyo
VOVictoria O. Oladoyin
Victoria O. Oladoyin
KOKorede Oluwatuyi
Korede Oluwatuyi
AOAdeayo O. Omotehinse
Adeayo O. Omotehinse
Chronic kidney disease has become a global pandemic, with its burden felt mostly in developing countries where there is a deficiency or outright lack of policy and funding for chronic kidney disease prevention and treatment. In Nigeria, its prevalence stands at about 13%, with the majority living in rural settings, far flung from nephrologists. The recent success achieved in integrating chronic kidney disease into primary healthcare has yet to receive significant funding from many governments, including Nigeria. Sustaining efforts towards disease prevention remains unachievable, with renal teams only embarking on one-off community outreaches that often fail to diagnose the disease. Contribution: In this article, the authors propose an adaptation of the nephrology clinic extension-mentorship model, which is designed to enable community-based kidney care that is anchored on nephrology teams acting as the fulcrum and basic functional unit. The model focuses on setting up semi-autonomous, quasi-renal clinics in local government areas in communities across Nigeria that will serve as platforms for sustained community engagement and participation in kidney care. The model also systematically entrenches continual screening and diagnosis of chronic kidney disease amongst at-risk groups within and outside the health centre premises through the provision of laboratory equipment and personnel that are specific for the purpose.